News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
261,276 Results
Type
Article (13591)
Company Profile (110)
Press Release (247575)
Section
Business (87975)
Career Advice (461)
Deals (15327)
Drug Delivery (64)
Drug Development (36532)
Employer Resources (49)
FDA (6259)
Job Trends (6184)
News (150058)
Policy (14008)
Tag
Academia (435)
Alliances (23095)
Alzheimer's disease (351)
Approvals (6253)
Artificial intelligence (61)
Bankruptcy (143)
Best Places to Work (4325)
Biotechnology (44)
Breast cancer (42)
Cancer (313)
Career advice (405)
Cell therapy (44)
Clinical research (30398)
Collaboration (153)
Compensation (62)
COVID-19 (747)
C-suite (52)
Data (342)
Diabetes (53)
Diagnostics (1237)
Drug pricing (57)
Earnings (31580)
Employer resources (43)
Events (36746)
Executive appointments (171)
FDA (6438)
Funding (104)
Gene therapy (59)
GLP-1 (292)
Government (1266)
Healthcare (3521)
Infectious disease (764)
Inflammatory bowel disease (46)
Interviews (58)
IPO (5816)
Job creations (2049)
Job search strategy (372)
Layoffs (167)
Legal (3411)
Lung cancer (46)
Manufacturing (99)
Medical device (1261)
Medtech (1263)
Mergers & acquisitions (9544)
Metabolic disorders (166)
Neuroscience (449)
NextGen Class of 2024 (1580)
Non-profit (590)
Northern California (432)
Obesity (99)
Opinion (109)
Patents (52)
People (28456)
Pharmaceutical (64)
Phase I (7903)
Phase II (12853)
Phase III (11552)
Pipeline (183)
Policy (45)
Postmarket research (1400)
Preclinical (3164)
Radiopharmaceuticals (116)
Rare diseases (90)
Real estate (2629)
Regulatory (9822)
Research institute (562)
Resumes & cover letters (55)
Southern California (438)
Startups (1626)
United States (4257)
Vaccines (112)
Weight loss (78)
Date
Today (30)
Last 7 days (282)
Last 30 days (1244)
Last 365 days (12695)
2024 (11587)
2023 (14245)
2022 (19564)
2021 (20081)
2020 (19035)
2019 (14890)
2018 (11713)
2017 (13892)
2016 (13134)
2015 (15476)
2014 (12419)
2013 (10593)
2012 (11395)
2011 (11924)
2010 (10890)
Location
Africa (312)
Arizona (42)
Asia (19789)
Australia (2559)
California (1007)
Canada (598)
China (110)
Colorado (41)
Connecticut (41)
Europe (38776)
Florida (149)
Illinois (110)
Indiana (86)
Japan (43)
Kansas (51)
Maryland (154)
Massachusetts (876)
Minnesota (56)
New Jersey (420)
New York (278)
North Carolina (277)
Northern California (432)
Pennsylvania (283)
South America (498)
Southern California (438)
Texas (137)
Virginia (40)
Washington State (70)
261,276 Results for "eton pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results
November 12, 2024
·
11 min read
Press Releases
Eton Pharmaceuticals Awarded Second Patent for ET-400 (Hydrocortisone Oral Solution)
November 7, 2024
·
3 min read
Business
Eton Pharmaceuticals Reports First Quarter 2024 Financial Results
Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, reported financial results for the quarter ended March 31, 2024.
May 9, 2024
·
10 min read
Business
Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2024 financial results on Thursday, May 9, 2024.
April 29, 2024
·
1 min read
Press Releases
Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
November 7, 2024
·
1 min read
Policy
Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced the submission of a New Drug Application to the U.S. Food and Drug Administration for approval of ET-400, Eton’s proprietary patented formulation of hydrocortisone oral solution.
April 30, 2024
·
3 min read
Business
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter and year ended December 31, 2023.
March 14, 2024
·
11 min read
Press Releases
Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen
October 3, 2024
·
8 min read
BioMidwest
Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference - May 01, 2024
Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced that Sean Brynjelsen, Chief Executive Officer, and James Gruber, Chief Financial Officer, will present at the Citizens JMP Life Sciences Conference in New York as follows.
May 1, 2024
·
1 min read
Business
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024
Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter and full year 2023 financial results on Thursday, March 14, 2024.
February 29, 2024
·
1 min read
1 of 26,128
Next
